The University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute has been designated as a Center of Excellence by the MDS Foundation, making it the only center in Arkansas to become part of the foundation’s referral network of the top bone marrow disorder treatment centers in the world.
Bintrafusp alfa, a novel bispecific antibody, achieved an objective response rate of 22% in women with recurrent or metastatic cervical cancer in a phase II nonrandomized controlled trial.
